Article

Novel Hepatitis C Vaccine Induces T Cell Responses

Science Translational Medicine

Adenovirus-based vaccines can generate strong, broad, long-lasting, and functional T cell responses against hepatitis C virus (HCV) in healthy people, according to a study published in the Jan. 4 issue of .

Eleanor Barnes, M.D., of the University of Oxford in the United Kingdom, and colleagues used a recombinant adenoviral vector strategy in a phase 1 trial of an HCV vaccine in healthy human volunteers. Two adenoviral vectors expressing NS proteins from HCV genotype 1B were constructed based on rare serotypes (human adenovirus 6 and chimpanzee adenovirus 3).

The researchers found that both of the vectors primed T cell responses against HCV proteins.

Read more at: http://www.physiciansbriefing.com/Article.asp?AID=660393

Source: HealthDay

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo